Compare
Merck & Co., Inc. vs Eli Lilly & Co vs Pfizer Inc vs AbbVie Inc.
| Latest fiscal year | Merck & Co., Inc. MRK | Eli Lilly & Co LLY | Pfizer Inc PFE | AbbVie Inc. ABBV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $65.01B | $65.18B | $62.58B | $61.16B |
| Revenue growth (YoY) | +1.3% | +44.7% | -1.6% | +8.6% |
| Gross margin | 74.8% (computed) | 83.0% (computed) | 74.3% (computed) | 70.2% (computed) |
| Operating margin | n/a | n/a | n/a | 24.6% |
| Net margin | 28.1% | 31.7% | 12.4% | 6.9% |
| Net income | $18.25B | $20.64B | $7.77B | $4.23B |
| EPS (Diluted) | $7.28 | $22.95 | $1.36 | $2.36 |
| Operating cash flow | $16.47B | $16.81B | $11.70B | $19.03B |
| Free cash flow | $12.36B | n/a | $9.07B | $17.82B |
| Cash & equivalents | $14.56B | $7.27B | $1.14B | $5.23B |
| Total assets | $136.87B | $112.48B | $208.16B | $133.96B |
| Total liabilities | n/a | n/a | $121.39B | n/a |
| Shareholders' equity | $52.66B | $26.54B | $86.78B | -$3.27B |
| Return on year-end equity | 34.7% | 77.8% | 9.0% | n/a |
| Shares outstanding | n/a | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Merck & Co., Inc. | Eli Lilly & Co | Pfizer Inc | AbbVie Inc. |
|---|---|---|---|---|
| Latest | $65.01B Ended 2025-12-31 | $65.18B Ended 2025-12-31 | $62.58B Ended 2025-12-31 | $61.16B Ended 2025-12-31 |
| 1 year earlier | $64.17B Ended 2024-12-31 | $45.04B Ended 2024-12-31 | $63.63B Ended 2024-12-31 | $56.33B Ended 2024-12-31 |
| 2 years earlier | $60.12B Ended 2023-12-31 | $34.12B Ended 2023-12-31 | $59.55B Ended 2023-12-31 | $54.32B Ended 2023-12-31 |
| 3 years earlier | $59.28B Ended 2022-12-31 | $28.54B Ended 2022-12-31 | $101.17B Ended 2022-12-31 | $58.05B Ended 2022-12-31 |
| 4 years earlier | $48.70B Ended 2021-12-31 | $28.32B Ended 2021-12-31 | $81.29B Ended 2021-12-31 | $56.20B Ended 2021-12-31 |